Myriad Genetics INC Form 4 insider transactions

Myriad Genetics' Chief Scientific Officer, Dale Muzzey, was awarded 23,697 shares of common stock following the achievement of performance metrics for previously granted restricted stock units.

Myriad Genetics' Chief Technology Officer, Kevin Richard Haas, was awarded 23,697 shares of common stock following the achievement of performance metrics for previously granted restricted stock units.

Myriad Genetics Chief Scientific Officer Dale Muzzey disposed of 418 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Myriad Genetics CFO Benjamin Wheeler disposed of 21 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Myriad Genetics Inc. CEO Samraat S. Raha disposed of 29,634 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Margaret Ancona, EVP of Strategy & Transformation at Myriad Genetics, will cease her role effective November 3, 2025, as reported in a recent Form 4 filing.

Natalie Munk, Chief Accounting Officer of Myriad Genetics Inc., has ceased her role and is no longer subject to Section 16 reporting requirements as of October 24, 2025.

Myriad Genetics Chief Operating Officer Mark Verratti disposed of 1,085 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Myriad Genetics' Chief Accounting Officer, Natalie Munk, reported the disposition of 962 shares for tax withholding related to restricted stock unit vesting.

Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, disposed of 2,559 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Myriad Genetics EVP Margaret Ancona reported the withholding of 958 shares of common stock to cover tax obligations related to vested restricted stock units.

Myriad Genetics' Chief Legal Officer, Jennifer Lynne Fox, disposed of 4,435 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, was granted 60,000 restricted stock units, increasing his beneficial ownership to 95,210 shares.

Myriad Genetics Inc. reports the departure of Chief Financial Officer Scott J. Leffler, effective August 15, 2025, as disclosed in a Form 4 filing.

Myriad Genetics Inc. Director Heinrich Dreismann has increased his beneficial ownership by 49,796 shares of common stock through a restricted stock unit grant, bringing his total holdings to 171,444 shares.

Myriad Genetics Inc. Director Paul Bisaro was granted 49,796 restricted stock units, increasing his beneficial ownership to 89,941 shares, aligning his interests with shareholders.

Myriad Genetics Inc. Director S. Louise Phanstiel reported the acquisition of 49,796 shares of common stock through a restricted stock unit grant on June 5, 2025, increasing her total beneficial ownership to 177,444 shares.

Myriad Genetics Inc. Director Mark Steven Davis was granted 24,148 restricted stock units of common stock on June 5, 2025, increasing his direct beneficial ownership to 46,964 shares.

Myriad Genetics Inc. Director Lee Nisley Newcomer reported the acquisition of 49,796 shares of common stock through a restricted stock unit grant on June 5, 2025, increasing her total beneficial ownership to 132,141 shares.

Myriad Genetics Inc. Director Colleen F. Reitan was granted 49,796 restricted stock units, increasing her beneficial ownership to 92,329 shares.

Myriad Genetics Inc. Director Rashmi Kumar was granted 49,796 restricted stock units, increasing her beneficial ownership in the company to 127,188 shares.

Myriad Genetics, Inc. Director Daniel Skovronsky has acquired 49,796 shares of common stock in the form of restricted stock units, as disclosed in a recent SEC Form 4 filing.

Myriad Genetics, Inc. President and CEO, Samraat S. Raha, acquired 1,498 shares of common stock on May 31, 2025, through the company's Employee Stock Purchase Plan.

Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics, reports the acquisition of time-based and performance-based restricted stock units.

Mark Verratti, Chief Operating Officer of Myriad Genetics, was granted performance-based restricted stock units (PSUs) on April 30, 2025, tied to the company's stock price performance.

Myriad Genetics CEO Samraat S. Raha was granted 141,050 performance-based restricted stock units (PSUs) tied to the company's stock price performance.

Paul Diaz, former President and CEO of Myriad Genetics, files a Form 4 to report his departure from the company, effective April 30, 2025.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, sold shares to cover tax obligations related to vesting restricted stock units.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.